eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Share:
Share:
abstract:
Original paper

Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation

Piotr Chodór
1
,
Krzysztof Wilczek
2
,
Łukasz Włoch
1
,
Roman Przybylski
3
,
Jan Głowacki
4
,
Tomasz Kukulski
1
,
Tomasz Niklewski
3
,
Marian Zembala
3
,
Zbigniew Gąsior
2
,
Zbigniew Kalarus
1

1.
Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland
2.
3rd Department of Cardiology, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland
3.
Department of Cardiac Surgery and Transplantology, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland
4.
Diagnostic Department, Department of Radiology, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland
Adv Interv Cardiol 2019; 15, 2 (56): 167–175
Online publish date: 2019/06/26
View full text Get citation
 
Introduction
The presence of coronary artery disease (CAD) in patients who underwent transcatheter aortic valve implantation (TAVI) may increase in-hospital and long-term mortality.

Aim
To evaluate the impact of CAD in patients who underwent TAVI.

Material and methods
The study group consisted of the first 142 patients treated with TAVI between 26 November 2008 and 31 December 2015. The patients were divided into two groups: group I comprised 103 (72.5%) patients with CAD, and group II comprised 39 (27.5%) patients without CAD.

Results
Group I was characterized by a significantly higher risk according to EuroSCORE – 11.2 ±2.5 vs. 9 ±2.3 in group II (p < 0.001) and Logistic EuroSCORE – 25.4 ±13.4 vs. 16.3 ±8.7 (p < 0.001). 30-day mortality was 8 (7.8%) vs. 2 (5.1%) (p = NS) and 1-year mortality was 22 (21.4%) vs. 6 (15.4%) (p = NS) in group I and II respectively. The composite endpoint evaluating the efficacy of TAVI was achieved in 82 (79.6%) vs. 31 (79.5%) (p = NS) in group I and II respectively. The composite endpoint, which involved 30-day observation, occurred in 39 (37.86%) vs. 12 (30.77%) (p = NS) and the composite endpoint, which involved 1-year evaluation of the clinical efficacy of TAVI, occurred in 48 (57.8%) vs. 13 (48.1%) (p = NS) in patients with and without CAD respectively.

Conclusions
The short- and mid-term outcomes of TAVI patients with CAD, despite higher risk profile, did not differ from the outcomes of treatment in patients without CAD.

keywords:

percutaneous coronary intervention, coronary artery disease, coronary artery bypass graft, transcatheter aortic valve implantation

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.